SecBot SecBot
8-K ·Filed Apr 27, 2026

FOLD

AMICUS THERAPEUTICS, INC.
NEUTRAL
Impact 9/10
Horizonimmediate Processed6mo ago SEC0001140361-26-016968
8-K material event: Items 1.02, 2.01, 5.01
Actionable Insight • Neutral

The stock will cease trading following delisting, and FOLD shareholders have been paid out in full. No further corporate actions are expected as Amicus operates as a private subsidiary of BioMarin. Monitor BioMarin's financial reports for integration updates.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$14.49
T+0 close · Apr 27, 2026 · via day close
Latest settled
0.00%
T+1 · $14.49
Vs SPY
+0.49%
α at T+1
Next horizon
T+5
due 7mo ago
  1. T+0 · Apr 27 $14.49entry
  2. T+1 · 7mo ago 0.00%α +0.49% · $14.49
  3. T+5 · due 7mo ago Pending
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Amicus Therapeutics completed its acquisition by BioMarin Pharmaceutical, resulting in a change of control, delisting from Nasdaq, and termination of its credit agreement. All directors and executive officers resigned, with BioMarin appointing new leadership. Shareholders received $14.50 per share in cash.

Key Facts

  • Merger with BioMarin Pharmaceutical completed on April 27, 2026, with Amicus becoming a wholly owned subsidiary.
  • Shareholders received $14.50 per share in cash as merger consideration.
  • Company common stock to be delisted from Nasdaq; Form 25 filed for deregistration.
  • All nine directors and five executive officers resigned; BioMarin appointees took over leadership roles.
  • Amended and restated certificate of incorporation reduces authorized shares to 100 common shares.
  • Credit agreement with Blackstone and Wilmington Trust terminated; all debt repaid.

Financial Impact

$14.50 per share cash payment to shareholders; full repayment of outstanding credit facility

equitydebtliquiditymarket capitalization

Risk Factors

  • Loss of public market liquidity for former shareholders
  • Integration risks within BioMarin's organization

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
43% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-016968
Document: ef20071351_8k.htm0001140361-26-016968
Document: ef20071351_ex3-1.htm0001140361-26-016968
Document: 0001140361-26-016968-index-headers.html0001140361-26-016968
Document: 0001140361-26-016968-index.html0001140361-26-016968
Document: 0001140361-26-016968.txt0001140361-26-016968

Track record

3 reports on FOLD

Performance horizon
Filters
  1. May 7, 202627w ago 15-12G Neutral 4/10 No price data
  2. Apr 27, 202629w ago 8-K Neutral 9/10 Viewing Entry $14.49 No price data
  3. Apr 23, 202629w ago 8-K Neutral 6/10 Entry $14.49 No price data
Showing 3 of 3

US Market Status

Market Closed · Opens Wed (11h 6m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026